Go Deep
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,195 | 9.1 | 5.70 | 0.07 | 2,107.52 |
| Oct 2026 | 18,562 | 9.7 | 6.42 | 0.07 | 2,247.41 |
| Oct 2026 | 18,162 | 9.6 | 6.77 | 0.07 | 2,369.28 |
| Oct 2026 | 18,325 | 10.0 | 6.63 | 0.07 | 2,312.94 |
| Oct 2026 | 18,165 | 10.3 | 6.76 | 0.07 | 2,363.77 |
| Oct 2026 | 17,799 | 10.7 | 7.08 | 0.07 | 2,474.71 |
| Oct 2026 | 17,824 | 10.7 | 7.06 | 0.07 | 2,461.03 |
| Oct 2026 | 17,984 | 10.5 | 6.92 | 0.07 | 2,407.91 |
Nurix Therapeutics, Inc. Quarterly Results
| Line Item | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 |
|---|---|---|---|---|
| Revenue | 9,043,000.0 | 6,252,000.0 | 13,577,000.0 | 7,894,000.0 |
| Net Profit | -89,535,000.0 | -87,174,000.0 | -78,221,000.0 | -86,421,000.0 |
| EPS | -0.8 | -0.8 | -0.8 | -1.0 |
Nurix Therapeutics, Inc. Revenue & Profit: Last 4 Years
| Line Item | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 |
|---|---|---|---|---|
| Revenue | 83,980,000.0 | 54,549,000.0 | 76,987,000.0 | 38,627,000.0 |
| Net Profit | -264,457,000.0 | -193,569,000.0 | -143,948,000.0 | -180,360,000.0 |
| EPS | -3.0 | -2.9 | -2.6 | -3.7 |
Nurix Therapeutics, Inc. Balance Sheet
| Line Item | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|
| Total Assets | 688,135,000.0 | 669,343,000.0 | 355,598,000.0 | 416,759,000.0 | — |
| Total Liabilities | 149,388,000.0 | 142,350,000.0 | 155,105,000.0 | 113,063,000.0 | — |
| Total Equity | 538,747,000.0 | 526,993,000.0 | 200,493,000.0 | 303,696,000.0 | — |
Owes vs Owns
Nurix Therapeutics, Inc. owed $0.25 for every $1 it owned in May 2026, down from $0.27 in Nov 2022.
| Period | May 2026 | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.25× | 0.22× | 0.21× | 0.44× | 0.27× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Nurix Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Nov 2025
Cash & short-term investments 86.2%Fixed assets (tangible) 10.6%Other assets 3.2%
How it's funded — Nov 2025
Long-term debt 7.7%Payables 1.6%Other liabilities 12.0%Shareholders' equity 78.3%
| Line Item | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 592.9 | 609.6 | 287.9 | 309.1 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 73.0 | 45.9 | 48.0 | 29.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 7.4 | 63.9 |
| Other assets | 22.2 | 13.9 | 12.3 | 14.2 |
| Liabilities & equity | ||||
| Short-term debt | 2.8 | 8.0 | 7.5 | 5.5 |
| Long-term debt | 52.9 | 20.3 | 23.1 | 6.4 |
| Payables | 11.2 | 11.5 | 6.4 | 5.1 |
| Other liabilities | 82.4 | 102.6 | 118.1 | 96.0 |
| Shareholders' equity | 538.7 | 527.0 | 200.5 | 303.7 |
| Net tangible assets | 538.7 | 527.0 | 200.5 | 303.7 |
Nurix Therapeutics, Inc. Cash Flow
| Line Item | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|
| Operating Activities | -249,465,000.0 | -172,584,000.0 | -81,365,000.0 | -159,807,000.0 | — |
| Investing Activities | 147,853,000.0 | -257,713,000.0 | 68,301,000.0 | 27,198,000.0 | — |
| Financing Activities | 238,642,000.0 | 485,667,000.0 | 3,217,000.0 | 117,192,000.0 | — |